Receptor tyrosine kinase inhibitors: Are they real tumor killers? (Q38365290)

2 September 2017

1 reference

title

Receptor tyrosine kinase inhibitors: Are they real tumor killers? (English)

1 reference

2 September 2017

Friedemann Kiefer

2

0 references

Georg Breier

object named as

Georg Breier

6

0 references

author name string

Andreas K A Gaumann

1

1 reference

2 September 2017

Joachim Alfer

3

1 reference

2 September 2017

Sven A Lang

4

1 reference

2 September 2017

Edward K Geissler

5

1 reference

2 September 2017

language of work or name

English

0 references

publication date

25 February 2015

1 reference

International Journal of Cancer

2 September 2017

number of pages

15

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

2 September 2017

volume

138

1 reference

2 September 2017

issue

3

1 reference

2 September 2017

page(s)

540-554

1 reference

Tumor angiogenesis: therapeutic implications

2 September 2017

cites work

1 reference

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

21 January 2018

1 reference

Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy

21 January 2018

1 reference

Molecular regulation of angiogenesis and lymphangiogenesis

21 January 2018

1 reference

Neuropilin regulation of angiogenesis, arteriogenesis, and vascular permeability

21 January 2018

1 reference

Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3.

21 January 2018

1 reference

Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis

21 January 2018

1 reference

Cooperative interaction of hypoxia-inducible factor-2alpha (HIF-2alpha ) and Ets-1 in the transcriptional activation of vascular endothelial growth factor receptor-2 (Flk-1)

21 January 2018

1 reference

Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene

21 January 2018

1 reference

Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele

21 January 2018

1 reference

Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice

21 January 2018

1 reference

VEGFA is necessary for chondrocyte survival during bone development

21 January 2018

1 reference

Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function

21 January 2018

1 reference

VEGF receptor signalling - in control of vascular function

21 January 2018

1 reference

Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases

21 January 2018

1 reference

VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells

21 January 2018

1 reference

Ras signaling directs endothelial specification of VEGFR2 vascular progenitor cells.

21 January 2018

1 reference

Axl is essential for VEGF-A-dependent activation of PI3K/Akt

21 January 2018

1 reference

VEGFR2 induces c-Src signaling and vascular permeability in vivo via the adaptor protein TSAd.

21 January 2018

1 reference

VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis

21 January 2018

1 reference

Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation

21 January 2018

1 reference

Intravital microscopy of tumor angiogenesis and regression in the dorsal skin fold chamber: mechanistic insights and preclinical testing of therapeutic strategies

21 January 2018

1 reference

Killing time for cancer cells

21 January 2018

1 reference

Regulation of endothelium-derived nitric oxide production by the protein kinase Akt

21 January 2018

1 reference

Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin.

21 January 2018

1 reference

Akt down-regulation of p38 signaling provides a novel mechanism of vascular endothelial growth factor-mediated cytoprotection in endothelial cells.

21 January 2018

1 reference

Signaling regulation of fetoplacental angiogenesis

21 January 2018

1 reference

Angiogenesis in cancer, vascular, rheumatoid and other disease

21 January 2018

1 reference

Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo

21 January 2018

1 reference

Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes

21 January 2018

1 reference

Angiogenic inhibitors: a new therapeutic strategy in oncology

21 January 2018

1 reference

Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.

21 January 2018

1 reference

Strategies to overcome resistance to targeted protein kinase inhibitors

21 January 2018

1 reference

Molecular basis for sunitinib efficacy and future clinical development

21 January 2018

1 reference

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

21 January 2018

1 reference

Targeting cancer with small molecule kinase inhibitors

21 January 2018

1 reference

Rational design of inhibitors that bind to inactive kinase conformations

21 January 2018

1 reference

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

21 January 2018

1 reference

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?

21 January 2018

1 reference

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

21 January 2018

1 reference

Regulation of vascular morphogenesis by Notch signaling

21 January 2018

1 reference

Tie receptors: new modulators of angiogenic and lymphangiogenic responses

21 January 2018

1 reference

Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis

21 January 2018

1 reference

Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure.

21 January 2018

1 reference

Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance

21 January 2018

1 reference

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

21 January 2018

1 reference

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

21 January 2018

1 reference

Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors

21 January 2018

1 reference

AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging

21 January 2018

1 reference

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

21 January 2018

1 reference

A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors

21 January 2018

1 reference

Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours

21 January 2018

1 reference

Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma

21 January 2018

1 reference

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study

21 January 2018

1 reference

Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis

21 January 2018

1 reference

Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study

21 January 2018

1 reference

Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study

21 January 2018

1 reference

CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone

21 January 2018

1 reference

Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer.

21 January 2018

1 reference

The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

21 January 2018

1 reference

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

21 January 2018

1 reference

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

21 January 2018

1 reference

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

21 January 2018

1 reference

21 January 2018

1 reference

Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer

21 January 2018

1 reference

Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice

21 January 2018

1 reference

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium

21 January 2018

1 reference

Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia

21 January 2018

1 reference

Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study

21 January 2018

1 reference

Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer

21 January 2018

1 reference

Motesanib diphosphate in progressive differentiated thyroid cancer.

21 January 2018

1 reference

Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.

21 January 2018

1 reference

Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate

21 January 2018

1 reference

Pazopanib: in advanced renal cell carcinoma

21 January 2018

1 reference

Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

21 January 2018

1 reference

Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials

21 January 2018

1 reference

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

21 January 2018

1 reference

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

21 January 2018

1 reference

A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer

21 January 2018

1 reference

Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer

21 January 2018

1 reference

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.

21 January 2018

1 reference

A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study

21 January 2018

1 reference

Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity.

21 January 2018

1 reference

Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors

21 January 2018

1 reference

Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo

21 January 2018

1 reference

Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.

21 January 2018

1 reference

A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas

21 January 2018

1 reference

Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma

21 January 2018

1 reference

Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma

21 January 2018

1 reference

A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial

21 January 2018

1 reference

Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis

21 January 2018

1 reference

Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2.

21 January 2018

1 reference

Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials

21 January 2018

1 reference

Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer

21 January 2018

1 reference

Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study

21 January 2018

1 reference

Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.

21 January 2018

1 reference

Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.

21 January 2018

1 reference

Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial

21 January 2018

1 reference

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

21 January 2018

1 reference

Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474.

21 January 2018

1 reference

Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model.

21 January 2018

1 reference

Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer

21 January 2018

1 reference

Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer

21 January 2018

1 reference

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial

21 January 2018

1 reference

Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary.

21 January 2018

1 reference

Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study.

21 January 2018

1 reference

Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer a

21 January 2018

1 reference

Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma.

21 January 2018

1 reference

Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials

21 January 2018

1 reference

Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib).

21 January 2018

1 reference

Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials

21 January 2018

1 reference

A phase 2 study of vatalanib in metastatic melanoma patients

21 January 2018

1 reference

Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).

21 January 2018

1 reference

Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer

21 January 2018

1 reference

Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma

21 January 2018

1 reference

Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours

21 January 2018

1 reference

EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma

21 January 2018

1 reference

Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia

21 January 2018

1 reference

Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins

21 January 2018

1 reference

Vascular endothelial growth factor D is dispensable for development of the lymphatic system

21 January 2018

1 reference

Neuropilin-2 regulates the development of selective cranial and sensory nerves and hippocampal mossy fiber projections.

21 January 2018

1 reference

Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium

21 January 2018

1 reference

Cardiovascular failure in mouse embryos deficient in VEGF receptor-3

21 January 2018

1 reference

Abnormal kidney development and hematological disorders in PDGF beta-receptor mutant mice.

21 January 2018

1 reference

Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret

21 January 2018

1 reference

Defects in enteric innervation and kidney development in mice lacking GDNF

21 January 2018

1 reference

Distinct types of tumors exhibit differential grade of inflammation and angiogenesis in mice

21 January 2018

1 reference

Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase

21 January 2018

1 reference

Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes

21 January 2018

1 reference

ApcMin, a mutation in the murine Apc gene, predisposes to mammary carcinomas and focal alveolar hyperplasias

21 January 2018

1 reference

A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors

21 January 2018

1 reference

Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions.

21 January 2018

1 reference

Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.

21 January 2018

1 reference

Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma

21 January 2018

1 reference

Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma

21 January 2018

1 reference

Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.

21 January 2018

1 reference

Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer

21 January 2018

1 reference

Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma.

21 January 2018

1 reference

PDGF-A Signaling Is a Critical Event in Lung Alveolar Myofibroblast Development and Alveogenesis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.29499

1 reference

2 September 2017

1 reference